GCG and Obesity: There has been a dramatic increase in the use of the GLP‐1 (glucagon‐like peptide‐1) receptor agonists semaglutide and liraglutide, and the GLP‐1/glucose‐dependent insulinotropic polypeptide (GIP) receptor co‐agonist tirzepatide to treat obesity after clinical trials showed that semaglutide and tirzepatide were highly effective for weight reduction and after FDA approval for obesity.1, 2